{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:18:14Z","timestamp":1780636694220,"version":"3.54.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.thromres.2017.04.010","type":"journal-article","created":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T11:00:17Z","timestamp":1492081217000},"page":"184-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial"],"prefix":"10.1016","volume":"156","author":[{"given":"Yihong","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Lokhnygina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Berkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Breithardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Hacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme J.","family":"Hankey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Nessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.","family":"Piccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.A.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manesh R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2017.04.010_bb0005","first-page":"491","article-title":"An epidemiological survey of atrial fibrillation in China","volume":"43","author":"Zhou","year":"2004","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.thromres.2017.04.010_bb0010","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1161\/01.STR.0000087149.42294.8C","article-title":"Collaborative Group of China Multicenter Study of Cardiovascular E. Proportion of different subtypes of stroke in China","volume":"34","author":"Zhang","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.thromres.2017.04.010_bb0015","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1161\/STROKEAHA.113.002968","article-title":"Executive steering C, the RAFSI. Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial","volume":"45","author":"Wong","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.thromres.2017.04.010_bb0020","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1212\/WNL.0b013e31829bfde3","article-title":"Epidemiology of stroke and its subtypes in Chinese vs white populations: a systematic review","volume":"81","author":"Tsai","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.thromres.2017.04.010_bb0025","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jacc.2007.01.098","article-title":"Racial\/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation","volume":"50","author":"Shen","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2017.04.010_bb0030","first-page":"328","article-title":"Current knowledge and management recommendations of atrial fbrillation","volume":"14","author":"Huang","year":"2010","journal-title":"Chin. J. Card. Arrhythmias"},{"key":"10.1016\/j.thromres.2017.04.010_bb0035","first-page":"1","article-title":"Chinese consensus on the warfarin treatment for thromboembolism disease","volume":"52","author":"Cso","year":"2013","journal-title":"Chin. J. Intern. Med."},{"key":"10.1016\/j.thromres.2017.04.010_bb0040","first-page":"1206","article-title":"Anticoagulation control in atrial fibrillation patients present to outpatient clinic of cardiology versus anticoagulant clinics","volume":"118","author":"Du","year":"2005","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.thromres.2017.04.010_bb0045","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2017.04.010_bb0050","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation\u2014the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ. J."},{"key":"10.1016\/j.thromres.2017.04.010_bb0055","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ahj.2009.11.025","article-title":"Rivaroxaban\u2014once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study","volume":"159","author":"Committee ES, Investigators RAs","year":"2010","journal-title":"Am. Heart J."},{"key":"10.1016\/j.thromres.2017.04.010_bb0060","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/STROKEAHA.113.000990","article-title":"Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation","volume":"44","author":"Hori","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.thromres.2017.04.010_bb0065","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ahj.2014.06.005","article-title":"Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial","volume":"168","author":"Goto","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.thromres.2017.04.010_bb0070","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1253\/circj.CJ-88-0001","article-title":"Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version","volume":"74","author":"Group JCSJW","year":"2010","journal-title":"Circ. J."},{"key":"10.1016\/j.thromres.2017.04.010_bb0075","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jacc.2008.05.042","article-title":"Epidemiology, risk factors for stroke, and management of atrial fibrillation in China","volume":"52","author":"Hu","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2017.04.010_bb0080","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S1474-4422(10)70274-X","article-title":"Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial","volume":"9","author":"Diener","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.thromres.2017.04.010_bb0085","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.metabol.2014.09.004","article-title":"Conditional glucagon receptor overexpression has multi-faceted consequences for beta-cell function","volume":"63","author":"Omar","year":"2014","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.thromres.2017.04.010_bb0090","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","article-title":"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2017.04.010_bb0095","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11239-012-0725-7","article-title":"Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients","volume":"34","author":"Liang","year":"2012","journal-title":"J. Thromb. Thrombolysis"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384817302785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384817302785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T18:56:19Z","timestamp":1535914579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384817302785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":19,"alternative-id":["S0049384817302785"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2017.04.010","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2017.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}